{"entity":{"id":"nct07714668","kind":"trial","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","aka":[],"tldr":"A phase 2 trial of Farletuzumab-exatecan, Bevacizumab, Carboplatin in ovarian cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.","summary":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT07714668 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 171 participants planned, started 2026-08-13 and due to reach its primary completion in 2028-04-30. Interventions recorded: SYS6041, bevacizumab, SYS6041, carboplatin, bevacizumab, paclitaxel, carboplatin, bevacizumab, SYS6041, enlonstobart, bevacizumab. Conditions listed: Ovarian Cancer, Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07714668","url":"https://clinicaltrials.gov/study/NCT07714668"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["farletuzumab-exatecan","bevacizumab","carboplatin","paclitaxel"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07714668","phase":"2","setting":"An Open-label , Multicenter, Multicohort, Phase II Clinical Study Evaluating the Efficacy and Safety of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","enrolled":171,"outcomes":[]},"route":"/trials/nct07714668/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"farletuzumab-exatecan","kind":"drug","name":"Farletuzumab-exatecan","route":"/drugs/farletuzumab-exatecan/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}